Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 42-56

  Flaveny, ColinA ^a   Griffett, Kristine ^a   El Gendy, BahaaEl DienM ^c   Kazantzis, Melissa ^b   Sengupta, Monideepa ^a   Amelio, AntonioL ^d   Chatterjee, Arindam ^a   Walker, John ^a   Solt, LauraA ^b   Kamenecka, TheodoreM ^b   Burris, ThomasP ^a,e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c BENHA UNIVERSITY   (Egypt)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; LIVER X RECEPTOR; SR 9243; UNCLASSIFIED DRUG; MOLECULAR LIBRARY; ORPHAN NUCLEAR RECEPTOR; SR9243; SULFONAMIDE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; IC50; INFLAMMATION; LIPOGENESIS; LIVER TOXICITY; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; WEIGHT REDUCTION; ADMINISTRATION AND DOSAGE; AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; DRUG EFFECTS; DRUG SCREENING; HEPG2 CELL LINE; HT 29 CELL LINE; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHARMACOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GLYCOLYSIS; HEP G2 CELLS; HT29 CELLS; HUMANS; LIPOGENESIS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; ORGAN SPECIFICITY; ORPHAN NUCLEAR RECEPTORS; SMALL MOLECULE LIBRARIES; SULFONAMIDES; WEIGHT LOSS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937475615     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.05.007     Document Type: Article

References (53)

1. Baranowski M. Biological role of liver X receptors. J.Physiol. Pharmacol. 2008, 59(Suppl 7):31-55.
2. Beyea M.M., Heslop C.L., Sawyez C.G., Edwards J.Y., Markle J.G., Hegele R.A., Huff M.W. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J.Biol. Chem. 2007, 282:5207-5216.
3. Blancher C., Harris A.L. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev. 1998, 17:187-194.
4. Bonuccelli G., Tsirigos A., Whitaker-Menezes D., Pavlides S., Pestell R.G., Chiavarina B., Frank P.G., Flomenberg N., Howell A., Martinez-Outschoorn U.E., et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.
5. Carracedo A., Cantley L.C., Pandolfi P.P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 2013, 13:227-232.
6. Chajès V., Cambot M., Moreau K., Lenoir G.M., Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 2006, 66:5287-5294.
7. Chuu C.P., Lin H.P. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. Anticancer Res. 2010, 30:3643-3648.
8. Clegg D.J., Wortman M.D., Benoit S.C., McOsker C.C., Seeley R.J. Comparison of central and peripheral administration of C75 on food intake, body weight, and conditioned taste aversion. Diabetes 2002, 51:3196-3201.
9. Dang C.V. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc. 2007, 35-53.
10. Dang C.V., Lewis B.C., Dolde C., Dang G., Shim H. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J.Bioenerg. Biomembr. 1997, 29:345-354.
11. Darimont C., Avanti O., Zbinden I., Leone-Vautravers P., Mansourian R., Giusti V., Macé K. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes. Biochimie 2006, 88:309-318.
12. DeBerardinis R.J., Lum J.J., Hatzivassiliou G., Thompson C.B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008, 7:11-20.
13. Fritz V., Benfodda Z., Rodier G., Henriquet C., Iborra F., Avancès C., Allory Y., de la Taille A., Culine S., Blancou H., et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol. Cancer Ther. 2010, 9:1740-1754.
14. Furuta E., Okuda H., Kobayashi A., Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim. Biophys. Acta 2010, 1805:141-152.
15. Grefhorst A., Elzinga B.M., Voshol P.J., Plösch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J.Biol. Chem. 2002, 277:34182-34190.
16. Griffett K., Solt L.A., El-Gendy Bel.-D., Kamenecka T.M., Burris T.P. A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem. Biol. 2013, 8:559-567.
17. Huang W.C., Li X., Liu J., Lin J., Chung L.W. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol. Cancer Res. 2012, 10:133-142.
18. Jamroz-Wiśniewska A., Wójcicka G., Horoszewicz K., Bełtowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy Hig Med Dosw (Online) 2007, 61:760-785.
19. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J.Biol. Chem. 2002, 277:11019-11025.
20. Jung S.Y., Song H.S., Park S.Y., Chung S.H., Kim Y.J. Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression. Int. J. Oncol. 2011, 38:571-576.
21. Kim T.H., Kim H., Park J.M., Im S.S., Bae J.S., Kim M.Y., Yoon H.G., Cha J.Y., Kim K.S., Ahn Y.H. Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver. J.Biol. Chem. 2009, 284:15071-15083.
22. Koshiji M., Huang L.E. Dynamic balancing of the dual nature of HIF-1alpha for cell survival. Cell Cycle 2004, 3:853-854.
23. Laffitte B.A., Chao L.C., Li J., Walczak R., Hummasti S., Joseph S.B., Castrillo A., Wilpitz D.C., Mangelsdorf D.J., Collins J.L., et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA 2003, 100:5419-5424.
24. Lo Sasso G., Bovenga F., Murzilli S., Salvatore L., Di Tullio G., Martelli N., D'Orazio A., Rainaldi S., Vacca M., Mangia A., et al. Liver X receptors inhibit proliferation of human colorectal cancer cells and growth of intestinal tumors in mice. Gastroenterology 2013, 144:1497-1507.
25. Lu C.W., Lin S.C., Chen K.F., Lai Y.Y., Tsai S.J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J.Biol. Chem. 2008, 283:28106-28114.
26. Martinez-Outschoorn U.E., Prisco M., Ertel A., Tsirigos A., Lin Z., Pavlides S., Wang C., Flomenberg N., Knudsen E.S., Howell A., et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011, 10:1271-1286.
27. Mason P., Liang B., Li L., Fremgen T., Murphy E., Quinn A., Madden S.L., Biemann H.P., Wang B., Cohen A., et al. SCD1 inhibition causes cancer cell death by depleting mono-unsaturated fatty acids. PLoS ONE 2012, 7:e33823.
28. Meng Z.X., Nie J., Ling J.J., Sun J.X., Zhu Y.X., Gao L., Lv J.H., Zhu D.Y., Sun Y.J., Han X. Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia 2009, 52:125-135.
29. Miller D.H., Fischer A.K., Chu K.F., Burr R., Hillenmeyer S., Brard L., Brodsky A.S. T0901317 inhibits cisplatin-induced apoptosis in ovarian cancer cells [corrected]. Int. J. Gynecol. Cancer 2011, 21:1350-1356.
30. Mohanti B.K., Rath G.K., Anantha N., Kannan V., Das B.S., Chandramouli B.A., Banerjee A.K., Das S., Jena A., Ravichandran R., et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys. 1996, 35:103-111.
31. Nguyen-Vu T., Vedin L.L., Liu K., Jonsson P., Lin J.Z., Candelaria N.R., Candelaria L.P., Addanki S., Williams C., Gustafsson J.A., et al. Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism. Breast Cancer Res. 2013, 15:R51.
32. Notarnicola M., Altomare D.F., Calvani M., Orlando A., Bifulco M., D'Attoma B., Caruso M.G. Fatty acid synthase hyperactivation in human colorectal cancer: relationship with tumor side and sex. Oncology 2006, 71:327-332.
33. Notarnicola M., Tutino V., Calvani M., Lorusso D., Guerra V., Caruso M.G. Serum levels of fatty acid synthase in colorectal cancer patients are associated with tumor stage. J Gastrointest Cancer 2012, 43:508-511.
34. Ogino S., Shima K., Nosho K., Irahara N., Baba Y., Wolpin B.M., Giovannucci E.L., Meyerhardt J.A., Fuchs C.S. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1849-1858.
35. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
36. Phan L.M., Yeung S.C., Lee M.H. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol. Med. 2014, 11:1-19.
37. Phelan C.A., Weaver J.M., Steger D.J., Joshi S., Maslany J.T., Collins J.L., Zuercher W.J., Willson T.M., Walker M., Jaye M., Lazar M.A. Selective partial agonism of liver X receptor alpha is related to differential corepressor recruitment. Mol. Endocrinol. 2008, 22:2241-2249.
38. Rough J.J., Monroy M.A., Yerrum S., Daly J.M. Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells. J Ovarian Res 2010, 3:13.
39. Russo V. Metabolism, LXR/LXR ligands, and tumor immune escape. J.Leukoc. Biol. 2011, 90:673-679.
40. Scaglia N., Chisholm J.W., Igal R.A. Inhibition of stearoylCoA desaturase-1 inactivates acetyl-CoA carboxylase and impairs proliferation in cancer cells: role of AMPK. PLoS ONE 2009, 4:e6812.
41. Tu Y., Thupari J.N., Kim E.K., Pinn M.L., Moran T.H., Ronnett G.V., Kuhajda F.P. C75 alters central and peripheral gene expression to reduce food intake and increase energy expenditure. Endocrinology 2005, 146:486-493.
42. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
43. Vedin L.L., Gustafsson J.A., Steffensen K.R. The oxysterol receptors LXRalpha and LXRbeta suppress proliferation in the colon. Mol. Carcinog. 2012.
44. Viennois E., Mouzat K., Dufour J., Morel L., Lobaccaro J.M., Baron S. Selective liver X receptor modulators (SLiMs): what use in human health?. Mol. Cell. Endocrinol. 2012, 351:129-141.
45. Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D., Negro A., Sanvito F., Ponzoni M., Valentinis B., Bregni M., et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 2010, 16:98-105.
46. Wagner B.L., Valledor A.F., Shao G., Daige C.L., Bischoff E.D., Petrowski M., Jepsen K., Baek S.H., Heyman R.A., Rosenfeld M.G., et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 2003, 23:5780-5789.
47. Wang Y., Rogers P.M., Su C., Varga G., Stayrook K.R., Burris T.P. Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha. J.Biol. Chem. 2008, 283:26332-26339.
48. Warburg O., Wind F., Negelein E. The Metabolism of Tumors in the Body. J.Gen. Physiol. 1927, 8:519-530.
49. Wójcicka G., Jamroz-Wiśniewska A., Horoszewicz K., Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 2007, 61:736-759.
50. Yeung S.J., Pan J., Lee M.H. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell. Mol. Life Sci. 2008, 65:3981-3999.
51. Zaytseva Y.Y., Rychahou P.G., Gulhati P., Elliott V.A., Mustain W.C., O'Connor K., Morris A.J., Sunkara M., Weiss H.L., Lee E.Y., Evers B.M. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012, 72:1504-1517.
52. Zhang Y., Zhang X., Chen L., Wu J., Su D., Lu W.J., Hwang M.T., Yang G., Li S., Wei M., et al. Liver X receptor agonist TO-901317 upregulates SCD1 expression in renal proximal straight tubule. Am. J. Physiol. Renal Physiol. 2006, 290:F1065-F1073.
53. Zhao L.F., Iwasaki Y., Nishiyama M., Taguchi T., Tsugita M., Okazaki M., Nakayama S., Kambayashi M., Fujimoto S., Hashimoto K., et al. Liver X receptor α is involved in the transcriptional regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. Diabetes 2012, 61:1062-1071.